What are the options for anticoagulation needs in dialysis for patients with heparin-induced thrombocytopenia?

Seminars in Dialysis

Volumn 24, Issue 4, 2011, Pages 382-385

  Davenport, Andrew ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN;

ALGORITHM; CHEMICALLY INDUCED DISORDER; HUMAN; NOTE; RENAL REPLACEMENT THERAPY; THROMBOCYTOPENIA;

ALGORITHMS; ANTICOAGULANTS; HEPARIN; HUMANS; RENAL DIALYSIS; THROMBOCYTOPENIA;

EID: 80051827561     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2011.00916.x     Document Type: Note

References (15)

1. Jenq CC, et al.: Heparin induced thrombocytopenia: recognition, treatment, and prevention. Chest 126:S311-S337, 2004
2. Warkentin TE, et al. (eds): Heparin Induced Thrombocytopenia, 3rd edn. New York: Marcel Dekker Inc, 2004
3. Murray PT, et al.: A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int 66:2446-2453, 2004
4. Davenport A: Antibodies to heparin-platelet factor 4 complex: pathogenesis, epidemiology, and management of heparin-induced thrombocytopenia in hemodialysis. Am J Kidney Dis 54:361-374, 2009
5. Greinacher A, et al.: The direct thrombin inhibitor hirudin. Thromb Haemost 99:819-829, 2008
6. Benz K, et al.: Hemofiltration of recombinant hirudin by different hemodialyzer membranes, implications for clinical use. Clin J Am Soc Nephrol 2:470-476, 2007
7. Eichler P, et al.: Antihirudin antibodies in patients with heparin induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 96:2373-2378, 2000
8. Kramel K, et al.: Heparin induced thrombocytopenia therapeutic concentrations of danaparoid, unlike fondaprinux and direct thrombin inhibitors inhibit formation of platelet factor 4 -heparin complexes. J Thromb Haemost 6:2160-2167, 2008
9. Sombolos KI, et al.: Use of fondaparinux as an anticoagulant during hemodialysis: a preliminary study. Int J Clin Pharmacol Ther 46:198-203, 2008
10. Davenport A: Anticoagulation options for haemodialysis. Minerva Urol Nefrol 58:171-180, 2006
11. Matsuo T, et al.: Can nafamostat mesilate be used for temporary management of hemodialysis in a patient with heparin-induced thrombocytopenia (HIT)? Thromb Haemost 86:1115-1116, 2001
12. Ahmad S, et al.: Dialysate made from dry chemicals using citric acid increases dialysis dose. Am J Kidney Dis 35:493-499, 2000
13. Davenport A: Central venous catheters for haemodialysis: how to overcome the problems. Hemodial Int 4:78-82, 2000
14. Schenk P, et al.: Recombinant tissue plasminogen activator is a useful alternative to heparin in priming Quinton permcath. Am J Kidney Dis 35:130-136, 2000
15. Willicombe MK, et al.: Embolic complications from central venous hemodialysis catheters used with hypertonic citrate locking solution. Am J Kidney Dis 55:348-351, 2010